TY - JOUR
T1 - Cyclotrimerization approach to unnatural structural modifications of pancratistatin and other amaryllidaceae constituents - Synthesis and biological evaluation
T2 - Canadian Journal of Chemistry
AU - Hudlicky, T.
AU - Moser, M.
AU - Banfield, S.C.
AU - Rinner, U.
AU - Chapuis, J.-C.
AU - Pettit, G.R.
N1 - Export Date: 13 June 2023; Cited By: 31; Correspondence Address: T. Hudlicky; Department of Chemistry, Centre for Biotechnology, Brock University, St. Catharines, Ont. L2S 3A1, 500 Glenridge Avenue, Canada; email: [email protected]; CODEN: CJCHA
PY - 2006/10
Y1 - 2006/10
N2 - The phenanthridone core of pancratistatin lacking all aromatic oxygenation was prepared by cyclotrimerization of acetylene-containing scaffolds 30 and 41, reflecting the natural and the C-1 epi configuration, respectively, of the amino inositol moiety. The cobalt-catalyzed formation of the aromatic core led to bisTMS derivatives 39 and 48, as well as bisacetyl derivative 51. The effectiveness of cyclotrimerization of the natural or trans series was compared with that of the cis series. In addition, the yields of cyclotrimerization were compared for propargylic amines and propargylic amides. Eleven derivatives, including the fully hydroxylated phenantridone 39, were tested against seven cancer cell lines. Three of the compounds displayed activities only an order of magnitude less than those of 7-deoxypancratistatin. Full experimental and spectral details are provided for all key compounds and future projections for the preparation of unnatural analogs of Amaryllidaceae constituents are advanced, along with some new insight into the minimum pharmacophore of pancratistatin. © 2006 NRC.
AB - The phenanthridone core of pancratistatin lacking all aromatic oxygenation was prepared by cyclotrimerization of acetylene-containing scaffolds 30 and 41, reflecting the natural and the C-1 epi configuration, respectively, of the amino inositol moiety. The cobalt-catalyzed formation of the aromatic core led to bisTMS derivatives 39 and 48, as well as bisacetyl derivative 51. The effectiveness of cyclotrimerization of the natural or trans series was compared with that of the cis series. In addition, the yields of cyclotrimerization were compared for propargylic amines and propargylic amides. Eleven derivatives, including the fully hydroxylated phenantridone 39, were tested against seven cancer cell lines. Three of the compounds displayed activities only an order of magnitude less than those of 7-deoxypancratistatin. Full experimental and spectral details are provided for all key compounds and future projections for the preparation of unnatural analogs of Amaryllidaceae constituents are advanced, along with some new insight into the minimum pharmacophore of pancratistatin. © 2006 NRC.
KW - Alkaloids
KW - Cobalt catalyst
KW - Cyclotrimerization
KW - Acetylene
KW - Amino acids
KW - Catalysts
KW - Cobalt
KW - Derivatives
KW - 1,2,3,4 tetrahydroxy 8,9 di(trimethylsilyl) 1,2,3,4,4a,5,6,10b octahydro 6 phenanthridine
KW - 11 hydroxy 2,2 dimethyl 4 (4 methylphenylsulfonyl) 10 phenylcarbonyloxy 7,8 di(trimethylsilyl) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridine
KW - 2,2 dimethyl 4 (4 methylphenylsulfonyl) 10 phenylcarbonyloxy 11 (tert butyldimethylsilyloxy) 7,8 di(trimethylsilyl) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridine
KW - 2,2 dimethyl 4 (4 methylphenylsulfonyl) 10,11 di(phenylcarbonyloxy) 7,8 di(trimethylsilyl) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridine
KW - 2,2 dimethyl 4 (4 methylphenylsulfonyl) 11 (tert butyldimethylsilyloxy) 7,8 di(trimethylsilyl) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridin 10 ol
KW - 2,2 dimethyl 4 (4 methylphenylsulfonyl) 5 oxo 10 phenylcarbonyloxy 11 (tert butyldimethylsilyloxy) 7,8 di(trimethylsilyl) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridine
KW - 2,2 dimethyl 4 (4 methylphenylsulfonyl) 5 oxo 10,11 di(phenylcarbonyloxy) 7,8 di(trimethylsilyl) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridine
KW - 2,2 dimethyl 4 (4 methylphenylsulfonyl) 7,8 di(trimethylsilyl) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridin 10,11 diol
KW - 2,2 dimethyl 4 (4 methylphenylsulfonyl) 7,8 di(trimethylsilyl) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridine 10,11 diol
KW - 2,2 dimethyl 4 [4 methylphenyl (3 trimethylsilyl 2 propynyl)sulfonamido] 5 (2 trimethylsilyl 1 ethynyl) 3a,4,5,7a tetrahydro 1,3 benzodioxole
KW - 2,2 dimethyl 7 (4 methylphenyl (2 propynyl)sulfonamido) 4 (tert butyldimethylsilyloxy) 5 phenylcarbonyloxy 6 (1 ethynyl)perhydro 1,3 benzodioxole
KW - 2,2 dimethyl 7 (4 methylphenylsulfonamido) 4 (tert butyldimethylsilyloxy) 5 phenylcarbonyloxy 6 (1 ethynyl)perhydro 1,3 benzodioxole
KW - 2,2 dimethyl 7 (4 methylphenylsulfonamido) 4,5 di(phenylcarbonyloxy) 6 (2 trimethylsilyl 1 ethynyl)perhydro 1,3 benzodioxole
KW - 4 hydroxy 2,2 dimethyl 7 (4 methylphenylsulfonamido) 5 phenylcarbonyloxy 6 (1 ethynyl)perhydro 1,3 benzodioxole
KW - 4 hydroxy 2,2 dimethyl 7 (4 methylphenylsulfonamido) 5 phenylcarbonyloxy 6 (2 trimethylsilyl 1 ethynyl)perhydro 1,3 benzodioxole
KW - 5 (1 ethynyl) 2,2 dimethyl 4 [4 methylphenyl(propioloyl)sulfonamido] 3a,4,5,7a tetarhydro 1,3 benzodioxolone
KW - 5 (4 methylphenylsulfonyl) 8,9 di(trimethylsilyl) 1,2,3,4,4a,5,6,10b octahydro 1,2,3,4 phenanthridinetetraol
KW - 5,5 dimethyl 7 (4 methylphenylsulfonyl) 10,11 di(trimethylsilyl) 3a,3b,6a,6b,7,8,12b,12c octahydro 1,3,4,6 tetraoxa 2 thia 7 azadicylcopenta[a,c]phenathrene 2,2 dioxide
KW - 6 (1 ethynyl) 2,2 dimethyl 7 [4 methylphenyl(propynyl)sulfonamido] 4,5 di(phenylcarbonyloxy)perhydro 1,3 benzodioxole
KW - 6,7 dihydroxy 2,2 dimethyl 4 (4 methylphenylsufonamido) 5 (2 trimethylsilyl 1 ethynyl)perhydro 1,3 benzodioxole
KW - 7 deoxypancratistatin
KW - 7 hydroxy 2,2 dimethyl 4 (4 methylphenylsulfonamido) 5 (2 trimethylsilyl 1 ethynyl) 3a,4,7,7a tetrahydro 1,3 benzodioxole
KW - 7,8 diacetyl 2,2 dimethyl 4 (4 methylphenylsulfonyl) 10,11 di(phenylcarbonyloxy) 3a,3b,4,5,9b,10,11,11a octahydro[1,3]dioxolo[4,5 c]phenanthridine
KW - Amaryllidaceae alkaloid
KW - antineoplastic agent
KW - n (7,7 dimethyl 2,2 dioxo 4 trimethylsilanylethynyl hexahydro 1,3,6,8 tetraoxa 2lambda 6 thia as indacen 5 yl) 4 methylbenzenesulfonamide
KW - n [2 (2 trimethylsilylethynyl) 5,6 (isopropylidenedioxy)cyclohex 3 en 1 yl)]n propioloyl 4 methylbenzenesulfonamide
KW - n [2 (2 trimethylsilylethynyl) 5,6 (isopropylidenedioxy)cyclohex 3 en 1 yl] 4 methylbenzenesulfonamide
KW - n [2 trimethylsilylethynyl 5,6 (isopropylidenedioxy)cyclohex 3 en 1 yl] n (4 methylphenylsulfonyl) 2,2 dimethyl 5 oxo 9 trimethylsilyl 3a,3b,4,5,9b,11a hexahydro[1,3]dioxolo[4,5 c]phenanthridine 10 en 7 carboxamide
KW - pancratistatin
KW - unclassified drug
KW - Aromatic oxygenation
KW - Cobalt catalysts
KW - Pancratistatin
KW - animal cell
KW - article
KW - cancer cell
KW - catalysis
KW - chemical reaction
KW - controlled study
KW - drug activity
KW - drug structure
KW - drug synthesis
KW - human
KW - human cell
KW - hydroxylation
KW - mouse
KW - nonhuman
KW - oxygenation
KW - polymerization
KW - structure activity relation
KW - Aromatic compounds
U2 - 10.1139/V06-078
DO - 10.1139/V06-078
M3 - Article
SN - 0008-4042
VL - 84
SP - 1313
EP - 1337
JO - Can. J. Chem.
JF - Can. J. Chem.
IS - 10
ER -